Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method

Research output: Contribution to journalJournal articleResearchpeer-review


  1. ECMM CandiReg-A ready to use platform for outbreaks and epidemiological studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates

    Research output: Contribution to journalJournal articleResearchpeer-review

  • A Espinel-Ingroff
  • M Arendrup
  • E Cantón
  • S Cordoba
  • E Dannaoui
  • J García-Rodríguez
  • G M Gonzalez
  • N P Govender
  • E Martin-Mazuelos
  • M Lackner
  • C Lass-Flörl
  • M J Linares Sicilia
  • M A Rodriguez-Iglesias
  • T Pelaez
  • R K Shields
  • G Garcia-Effron
  • J Guinea
  • M Sanguinetti
  • J Turnidge
View graph of relations

Method-dependent Etest epidemiological cutoff values (ECVs) are not available for susceptibility testing of either Candida or Aspergillus species with amphotericin B or echinocandins. In addition, reference caspofungin MICs for Candida spp. are unreliable. Candida and Aspergillus species wild-type (WT) Etest MIC distributions (microorganisms in a species-drug combination with no detectable phenotypic resistance) were established for 4,341 Candida albicans, 113 C. dubliniensis, 1,683 C. glabrata species complex (SC), 709 C. krusei, 767 C. parapsilosis SC, 796 C. tropicalis, 1,637 Aspergillus fumigatus SC, 238 A. flavus SC, 321 A. niger SC, and 247 A. terreus SC isolates. Etest MICs from 15 laboratories (in Argentina, Europe, Mexico, South Africa, and the United States) were pooled to establish Etest ECVs. Anidulafungin, caspofungin, micafungin, and amphotericin B ECVs (in micrograms per milliliter) encompassing ≥97.5% of the statistically modeled population were 0.016, 0.5, 0.03, and 1 for C. albicans; 0.03, 1, 0.03, and 2 for C. glabrata SC; 0.06, 1, 0.25, and 4 for C. krusei; 8, 4, 2, and 2 for C. parapsilosis SC; and 0.03, 1, 0.12, and 2 for C. tropicalis The amphotericin B ECV was 0.25 μg/ml for C. dubliniensis and 2, 8, 2, and 16 μg/ml for the complexes of A. fumigatus, A. flavus, A. niger, and A. terreus, respectively. While anidulafungin Etest ECVs classified 92% of the Candida fks mutants evaluated as non-WT, the performance was lower for caspofungin (75%) and micafungin (84%) cutoffs. Finally, although anidulafungin (as an echinocandin surrogate susceptibility marker) and amphotericin B ECVs should identify Candida and Aspergillus isolates with reduced susceptibility to these agents using the Etest, these ECVs will not categorize a fungal isolate as susceptible or resistant, as breakpoints do.

Original languageEnglish
JournalAntimicrobial Agents and Chemotherapy
Issue number1
Pages (from-to)e01792-16
Publication statusPublished - Jan 2017

    Research areas

  • Amphotericin B, Antifungal Agents, Aspergillus, Candida, Disk Diffusion Antimicrobial Tests, Drug Resistance, Fungal, Echinocandins, Europe, Latin America, South Africa, United States, Journal Article, Multicenter Study

ID: 52705261